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Purpose: The purpose of this study was to determine whether vascular smooth muscle cells (SMCs) suffused into a
bilayered stent graft retain and express a retrovirally transduced gene for 7 months in vivo.
Methods: SMCs harvested from dog jugular vein were retrovirally transduced to introduce genes for tissue plasminogen
activator (t-PA) and -galactosidase. These cells were then suffused into a novel dual-layered Dacron graft and cultured
for 36 to 48 hours. The grafts were mounted on a Palmaz stent and balloon- expanded in the infrarenal aorta of the SMC
donor dogs (n  6). Grafts were recovered at 1, 2, 3, 4, 5, and 7 months. A control endograft suffused with SMCs
transduced with only the -galactosidase gene was placed in the dogs with grafts recovered at 2, 3, and 4 months. t-PA
antigen concentration and expression were analyzed with an enzyme-linked immunosorbent assay.
Results: Retained engineered SMCs (blue nuclei) were identified in the explanted grafts, neointima, and underlying aorta
with X-gal staining. The t-PA antigen concentration and t-PA activity from the SMCs recovered from the grafts remained
elevated for the duration of the experiment (7 months) at levels significantly higher (3.7  0.2 ng/mL per 105 cells per
24 hours and 1.4  0.1 IU/mL per 105 cells per 24 hours) than in control endografts (0.5  0.03 ng/mL per 105 cells
per 24 hours and 0.07  0.00 IU/mL per 105 cells per 24 hours; P < .001). No graft stenosis was observed.
Conclusion: Retrovirally engineered vascular SMCs survived the implantation trauma, repopulated each graft, migrated
into the underlying aorta, and expressed the transduced genes for the 7-month duration of the experiment. This bilayered
Dacron endograft model provides a platform to study direct intravascular gene therapy. (J Vasc Surg 2004;39:1066-73.)The purpose of this study was to genetically engineer
prosthetic vascular grafts to deliver therapeutic enzymes
directly into the circulation. Potential benefits include
modulation of the kinetics of neointima formation, treat-
ment of vascular and other end organ diseases downstream
from the graft, and sustained systemic delivery of therapeu-
tic proteins. Last, while engineering cells in vitro to express
a particular enzyme is readily performed, studying them
after injection into tissue beds or embolization into organs
is difficult. Retrieval of these cells for study can be simplified
by delivering them into the circulation on a graft.
Seeding a polytetrafluoroethylene (PTFE) graft lumi-
nal surface with endothelial cells (ECs) has been advocated
as a means to reduce surface thrombogenicity and improve
graft patency.1,2 Seeding of ECs on an intravascular stent
was improves the patency of vessels after angioplasty3,4;
however, cell retention is impaired by implantation trauma
and the shear stress of flowing blood with both strategies.
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stent-graft technology5,6 and a novel dual-lumen thin Da-
cron graft surface.
Genetically engineered cells seeded onto grafts improve
graft surface characteristics.7,8 ECs and smooth muscle cells
(SMCs) have been induced to express tissue plasminogen
activator (t-PA) with retroviral engineering,9-11 and t-PA–
transduced cells have been seeded onto grafts.12-14 We
reported the suffusion of retrovirally engineered ECs and
SMCs onto polyurethane carbonate stent grafts deployed
in a pig model.15 The process of suffusion starts with cell
seeding of the luminal, abluminal, and lateral graft surfaces,
and ends with cell permeation throughout the graft matrix.
We observed survival of suffused cells, with growth
throughout the graft, as well as growth into the underlying
artery after implantation for 1 month. The neointima that
formed on the graft surface was densely populated with
genetically engineered cells.
In the current 7-month study, retrovirally engineered
SMCs suffused into a novel bilayered Dacron stent graft
expressed t-PA at constant high levels in dogs. Dacron was
selected because of its wide clinical use.
MATERIAL AND METHODS
Procedure outline. Vascular SMCs harvested from
the internal jugular vein of a dog were retrovirally trans-
duced to express t-PA and a reporter lacZ gene. The
engineered cells were then suffused into a dual-layered
Dacron graft mounted on a balloon-expanded stent and
implanted in the dog aorta with catheter technology. The
graft was later explanted and analyzed for t-PA antigen
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chromagen to enable identification of the engineered cells
(nuclei stain blue). Implanted stent grafts were harvested at
1, 2, 3, 4, 5, and 7 months from six separate dogs. Three
dogs also received a control stent graft. Cells in the control
graft were engineered to express lacZ but not t-PA. The
control grafts were harvested at 2, 3, and 4 months. Neo-
intimal thickness and surface thrombus were compared
between control and t-PA–secreting endografts.
Retroviral vector and cell transduction. Replication-
incompetent murine leukemia retrovirus (MuLV)
pseudotyped with the vesicular stomatitis virus G glyco-
protein (VSV-G) envelope was used to transduce the har-
vested SMCs from the dog jugular vein. The vectors were
generated from producer cell lines 293/GPG/X, where X
represents the vector plasmid. Vector plasmid G1nBgSvNa
contains a lacZ gene-encoding nuclear-localized -galacto-
sidase and a neomycin resistance gene (neor) encoding for
neomycin phosphotransferase. The vector plasmid LtSN
contains a gene encoding for wild-type human t-PA and a
neor gene, as described.14 The viral titers were 106 to 107
colony-forming units per milliliter, analyzed with neomy-
cin resistance assay. All gene transfers were mediated with
the VSV-G pseudotyped MuLV (VSV-G/MuLV) vectors
generated from the producer cell lines 293/GPG/X.
Transduction of SMCs with viral vectors was per-
formed11 by overlaying viral supernatants containing 8
g/mL of polybrene on cells plated on culture dishes for 2
hours. The transduction efficiency was determined by
counting the blue and the colorless cells under a micro-
scope after X-gal staining. Transduction efficiency was 90%
to 95%. To transduce both lacZ and t-PA genes into the
same SMCs, two vectors, G1nBgSvNa and LtSN, were
mixed and overlayed on the cell layers. Incubating cells
with the two vectors resulted in double transduction. The
efficiency of double transduction was determined in a sep-
arate experiment with two reporter genes: G1nBgSvNa for
lacZ and LGFPSN for green fluorescence protein. The
transduction efficiency range was 70% to 80% for each gene.
X-gal staining. The X-gal chromogen, 5-bromo-4-
chloro-3-indolyl -D-galactopyranoside (Research Prod-
ucts International Corp, Mt Prospect, Ill), was used to
detect the activity of -galactosidase in lacZ gene-
transduced cells. The cultured cells grown on a tissue
culture plate, or the recovered explanted and sectioned
tissues were washed with phosphate-buffered solution
(PBS) and fixed with PBS containing 0.2% glutaraldehyde
and 2% formaldehyde, for 10 minutes. After PBS rinsing at
room temperature for 3 to 10 minutes the tissues were
incubated with a PBS solution containing 1 mg/mL of
X-gal, 2 mmol/L of MgCl2, 4 mmol/L of K3Fe(CN)6 and
4 mmol/L of K4Fe(CN)6 for 4 to 10 hours at 37°C. Cells
expressing -galactosidase were blue. Transduction effi-
ciency was calculated with the ratio of blue cells to the total
population of cells contained in a viewing field.
t-PA activity and concentration assay. The enzyme
activity and antigen concentration of t-PA in medium con-
ditioned with transduced cells were measured withChromolize t-PA and Tintliz t-PA assay kits (Biopool,
Ventura, Calif). In brief, either SMCs (n 105) or graft (1
cm2) were cultured in a 24-well plate with Dulbecco mod-
ified Eagle medium (DMEM; Gibco, Grand Island, NY)
containing 0.1% fetal bovine serum for 24 hours. Each
conditioned medium was collected and centrifuged. t-PA
activity and antigen concentration in the supernatants were
assessed according to the manufacturer’s instructions. The
t-PA antigen concentration was expressed as nanograms
per milliliter per 105 cells. The t-PA activity was expressed
as international units per milliliter per 105 cells. Both
measures of t-PA expression were made after 24 hours in
culture medium.
In vivo procedures. The experimental protocol was
approved by the University of Miami Animal Care and Use
Committee. Six mongrel dogs weighing 15 to 20 kg un-
derwent three procedures: removal of the external jugular
vein for isolation of SMCs, implantation of grafts, and
retrieval of the grafts. For each procedure, dogs were fasted
overnight, and sedated with tiletamine and zolazepam in-
tramuscularly (IM). After the administration of atropine
intravenously (IV) the trachea was intubated, and general
anesthesia was induced with isoflurane. The skin was pre-
pared with betadine. Buprenorphine (IM) was used for
postoperative analgesia.
Harvesting of SMCs from the external jugular
vein. The external jugular vein was sterilely harvested,
transported in cell culture media, incised longitudinally,
and the intima was scraped off with a scalpel. The opened
vein was placed into tissue culture flasks and agitated in PBS
containing collagenase I (1.8 mg/mL) and elastase (0.2
mg/mL) for 1 hour at 37°C. The supernatant containing
suspended SMCs was removed and pelleted with centrifu-
gation at 1200 rpm for 5 minutes. The SMCs were resus-
pended and cultured in DMEM containing 20% fetal bo-
vine serum, L-glutamine (2 mmol/L), penicillin (50 units/
mL), streptomycin (50 g/m), gentamicin (2.5 g/mL),
and amphotericin B (2.5 g/mL). SMCs were passaged at
a ratio of 1:5, and were used for experiments between
passages 3 and 4. Cells containing smooth muscle -actin
were identified as SMCs.
Stent graft and cell suffusion. Each stent graft con-
tains a Palmaz stent (394) and two identical thin concentric
Dacron graft layers, each 1 mm thick. The Dacron graft
(Cordis, Miami Lakes, Fla) is 10 mm in diameter when fully
expanded, and was longitudinally crimped. The graft ma-
terial was Dacron type 56T. The yarn type was 40 de-
nier/27 filament for both ends and picks. The water per-
meability was less than 350 mL/cm2/min. The graft
thickness was 0.1 mm. The weave type was plain weave,
single ply. There were nine ends per millimeter, and 4.5
picks per millimeter. Each graft was cut to a length of 4 cm,
and fully expanded. The graft was sterilized by means of
immersion in 100% ethanol for 10 minutes, then immersed
for two 10-minute intervals in PBS to remove the ethanol.
Grafts were then immersed in culture medium containing
40 g/mL of fibronectin for 5 minutes. Each graft was
incubated at 37°C for 2 hours in a tube containing SMCs
JOURNAL OF VASCULAR SURGERY
May 20041068 Eton et altrypsinized from the 100-mm tissue culture plates. During
this time the tube was rolled 60 degrees every other minute
to achieve uniform distribution of cells on the graft. Then
the grafts were placed in a 100-mm culture dish and cul-
tured for 1 to 2 days. At the end of the incubation there
were approximately 105 cells/cm2 graft. One graft layer
was pulled into the other to create a single conduit formed
of two concentric Dacron graft layers.
The dual-layered Dacron graft containing the SMCs
was transported to the animal facility in cell culture medium
(see above). The dual-layered Dacron graft was then sewn
to the end of a Palmaz stent (394) with 6-0 polypropylene
(Prolene) sutures 180 degrees apart (Fig 1, A). This was
done with the graft material immersed in culture medium
and mixed with 30 mL of autologous heparinized dog
blood. The completed stent graft was then threaded over a
10-mm  4-cm balloon angioplasty catheter (Boston Sci-
entific, Natick, Mass). The stent graft was crimped onto the
balloon catheter with temporary loops of 2-0 silk suture to
Table I. t-PA production
Sample sources*
Duration
(mo)
Graft
Control
Antigen concentration (ng/mL/105 cells/24 h)
Pre-implant† 0 0.39  0.04 3
Post-implant‡ 1 NA
2 0.38
3 0.38
4 0.39
5 NA
7 NA
Post-selection§ 1 NA
2 0.45
3 0.46
4 0.51
5 NA
7 NA
Activity (IU/mL/105 cells/24 h)
Pre-implant† 0 0.01  0.01 1
Post-implant‡ 1 NA
2 0.07
3 0.06
4 0.06
5 NA
7 NA
Post-selection§ 1 NA
2 0.07
3 0.07
4 0.07
5 NA
7 NA
t-PA, Tissue plasminogen activator; SMC, smooth muscle cells; MuLV, mu
*SMC were transduced with MLV vector carrying the lacZ gene alone (SM
stent grafts and implanted into dog aorta. One dog was killed each month (1
two stent grafts were implanted, one seeded with SMC/lacZ (Control) and
only one graft seeded with SMC/t-PA was implanted. Cells (n 105) from
medium for 24 hours. The conditioned media were assayed with enzyme-li
†Pre-implant data were derived from the conditioned medium of SMCs bef
‡Post-implant (pre-selection) data were derived from the conditioned mediu
Fig 3, A).
§Post-selection data were derived from the conditioned medium of SMCs frocinch the stent down at 1-cm intervals. Care was taken to
keep the grafts submerged in the culture fluid–blood mix-
ture during this process.
Aortic stent-graft placement. Each dog received ce-
fazolin sodium (Ancef; 1 g IV) and heparin (100 units/kg
IV). A 14F introducer sheath was placed into the exposed
femoral artery (Fig 1, B). A 4F pigtail catheter was placed,
and 20 mL of contrast medium (Renograffin) was injected
to identify and mark the renal artery orifices. The assembled
stent graft mounted on a 10-mm  4-cm balloon angio-
plasty catheter was then threaded up the 14F sheath into
the infrarenal dog aorta over a 0.035-inch guide wire under
fluoroscopic guidance. The valve in the sheath was made
incompetent with a plastic sleeve. The stent graft was then
balloon-expanded into the aorta. In three dogs an addi-
tional dual-layered Dacron graft was placed as a control,
superior to the t-PA–transduced endograft. This control
graft was suffused with cells containing only the LacZ
reporter gene. The inferior graft was suffused with cells
Neointima Artery
A Control t-PA Control t-PA
0.53
A NA NA NA NA
8 0.50 1.54 0.52 1.33
8 0.49 1.27 0.49 1.27
0 0.51 1.16 0.47 1.22
5 NA 1.04 NA 0.92
6 NA 1.25 NA 0.92
A NA NA NA NA
2 0.54 3.65 0.48 3.39
2 0.49 3.79 0.47 3.76
6 0.51 3.87 0.50 3.49
9 NA 4.13 NA 3.50
6 NA 4.13 NA 3.46
0.53 NA NA NA NA
A NA NA NA NA
3 0.06 0.40 0.06 0.39
4 0.06 0.40 0.06 0.34
7 0.06 0.38 0.06 0.38
8 NA 0.38 NA 0.35
5 NA 0.38 NA 0.34
7 NA 1.50 NA 1.36
8 0.07 1.43 0.07 1.41
7 0.07 1.15 0.07 1.12
5 0.07 1.36 0.07 1.11
3 NA 1.21 NA 1.36
7 NA 1.25 NA 1.24
ukemia virus; NA, not applicable.
Z) and t-PA and lacZ genes (SMC/tPA). They were suffused into Dacron
4, 5, and 7 months) to recover grafts. For dogs killed at 2, 3, and 4 months,
ther seeded with SMC/t-PA (t-PA). For dogs killed at 1, 5, and 7 months,
ft, neointima, and underlying artery were cultured with 1 mL of serum-free
mmunosorbent assays for t-PA antigen concentration and t-PA activity.
aft suffusion.
SMCs recovered from Dacron grafts, neointima, and underlying artery (see
her the Dacron grafts, neointima, or underlying artery after G418 selection.t-P
.81 
N
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minimize contrast exposure a completion angiogram was
not obtained. The femoral artery was ligated, and the
wound was closed. Fluoroscopy showed the position of the
radiopaque stent grafts (Fig 1, C).
Graft explantation. With the dogs under general en-
dotracheal anesthesia, the abdominal aorta was explanted
sterilely through a midline laparotomy, and transported in
culture medium. In accordance with the Guidelines of the
Panel of Euthanasia of the American Veterinary Medical
Association, an overdose of sodium pentobarbital (120
mg/kg) was administered IV after explantation was
completed.
Analysis of recovered grafts. The samples, which
included the graft, neointima, and underlying aorta, were
rinsed with PBS. Each sample was cut in two. One part was
opened longitudinally. The gross appearance and degree of
thrombus formation were recorded. Thereafter, the SMCs
were dissociated from the graft with trypsin-ethylenedia-
mine tetraacetic acid for 7 minutes. The released cells were
resuspended, and expanded in culture. The neointima and
the artery were chopped into fine pieces and digested in
PBS containing type I collagenase (1.8 mg/mL ) and
elastase (0.2 mg/mL) for 1 hour at 37°C. The pelleted cells
were reconstituted in culture medium. The conditioned
medium, referred to as post-implant (Table I), was analyzed
for t-PA concentration and activity. These cells were then
selected with neomycin analog G418 (0.6 mg/mL) to
eliminate the untransduced (native) SMCs. The medium
from these G418-resistant cells was named post-selection
(Table I). t-PA activity and antigen concentrations from
the conditioned post-implant and post-selection media
were measured with an enzyme-linked immunosorbent
assay (Table I).
The remainder of the specimen was fixed with 0.2%
glutaraldehyde–2% formaldehyde in PBS, and stained with
X-gal. Stent struts were removed. The neointima layer was
separated from the Dacron material, which was also gently
separated from the underlying arterial wall. The neointima,
the Dacron material, the underlying artery, and the supra-
renal aorta were stained with X-gal, and photographed. The
samples were embedded in paraffin, and sectioned at 5 m.
Retention of the engineered cells was determined by
assessing the number of blue cells (-galactosidase–positive
cells). The neointima was examined with hematoxylin-
eosin (H&E) and Masson trichrome stains. The thickness
of the neointima was determined by using the average of
eight separate measurements along the circumference of
the neointima.
Statistical analysis. Experimental values were ex-
pressed as mean  SD. Statistically significant differences
between groups were compared with the two-tailed Stu-
dent t test. Significance was attributed at P  .05.
RESULTS
Gene transfer into SMCs. Isolated autologous SMCs
were transduced with retroviral vectors to generate two
groups of SMCs: control, transduced with a single vectorFig 1. Implantation of a Dacron stent graft. a, Dual-lumen Da-
cron graft longitudinally crimped and mounted on a 4-cm long
Palmaz stent. The graft was attached to the top of the stent with two
6-0 polypropylene stitches 180 degrees apart. The stent graft was
mounted on a balloon angioplasty catheter. b, The stent graft was
inserted into a 14F tube, slit along the back to decrease friction injury.
The 14F tube was then inserted into the back of a 14F introducer
sheath to make its valve incompetent. The introducer sheath was
positioned before this in the common femoral artery, with the
Seldinger technique. Once the valve was made incompetent, the stent
graft was advanced into the circulation seated on the 4-cm 10-mm
balloon angioplasty catheter. To avoid dehydration, the stent graft
was kept within the culture medium in the bowl during graft assembly
until just before deployment. c, Lateral abdominal x-ray film of two
stent grafts. The superior graft is the control non–t-PA graft, and the
inferior graft is the t-PA–engineered graft.
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activity, and test, transduced with two vectors to confer lacZ
and t-PA activity.
The t-PA antigen concentration from the t-PA gene–
transduced SMCs was 3.81 0.53 ng/mL per 105 cells per
24 hours (n  6) in the conditioned medium, 10-fold
higher than in the untransduced cells (0.39 0.04 ng/mL
per 105 cells per 24 hours). The corresponding t-PA activ-
ity from SMC/t-PA was 1.54 0.53 IU/mL per 105 cells
per 24 hours, which was more than 100-fold higher than in
untransduced cells (0.01 IU/mL per 105 cells per 24
hours; Table I).
Suffusion of cells into Dacron graft material. The
t-PA and lacZ co-transduced cells were suffused onto Da-
cron grafts. After 2 days in culture, X-gal staining showed
that the cell density on each Dacron graft reached 105
cells/cm2; Fig 2, A). t-PA activity in the cultured medium
of the SMC/t-PA graft reached 1.57 IU/mL/cm2 per 24
hours, compared with 0.07 IU/mL/cm2 per 24 hours in
the non-t-PA graft controls.
Retention of suffused cells. Two cell-seeded grafts
were sewn together concentrically. At implantation the
double-layered graft was sewn onto a stent. One dog was
killed monthly, and the grafts were explanted. The last graft
was explanted 7 months after implantation. No surface
thrombosis was observed on any of the harvested grafts.
After X-gal staining, blue-stained SMCs populated each
layer of the Dacron stent graft (Fig 2, B, E), the neointima
(Fig 2, C, F), and the artery underlying the stent graft (Fig
2, D). The SMCS from the implanted stent graft had clearly
proliferated to form a neointima, and had also migrated
into the underlying artery (Fig 2). Thus there was expres-
sion of the transduced reporter lacZ gene extending up to 7
months. In contrast, no -galactosidase activity was de-
Fig 2. Cell retention and gene expression on stent grafts. The
stent grafts were suffused with lacZ-transduced smooth muscle
cells and implanted into dog aorta. The suffused cells (blue) on the
Dacron graft before implantation (a) and 1 month after implanta-
tion (b) were observed at microscopy (original magnification40
and 100, respectively). Neointima cross section (c) stained with
X-gal and hematoxylin to show the engineered cells (blue) and
endogenous cells (pink) (original magnification250). X-gal stain
of the underlying artery (d), the Dacron material (e), the overlying
neointima (f), and the control suprarenal aorta (g).tected in the neighboring suprarenal (control) artery (Fig
2, G).
t-PA expression and production from recovered
cells. The suffused SMCs and their progeny were isolated
from each stent graft by digestion with collagenase and
elastase. t-PA antigen and activity were measured before
and after selection with G418 neomycin analog in cells
isolated from the Dacron graft, the neointima, and the
underlying aorta.
Fig 3. Neointima on Dacron stent graft. Recovered graft 7
months after implantation was fixed, and stent struts were re-
moved. The separated neointima, Dacron grafts, and artery were
sandwiched back and embedded. a, Schema of the recovered
endograft. b, Hematoxylin-eosin staining (original magnification
40). Black arrow, Space once occupied by the stent strut; White
arrow, neointima between two Dacron grafts; position 1, neointima
overlying the stent strut; position 2, neointima between struts.
Measurements for Table II were obtained from the neointima
thickness at positions 1 and 2. c, Masson trichrome staining
(original magnification 40). Blue coloring indicates presence of
collagen.
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neomycin resistance gene and the LacZ reporter gene for
this purpose. This was necessary because the neointima
forming on the grafts contained a mixture of transduced
SMCs, cells from the underlying artery that migrated
through the stent graft, and cells deposited from the blood-
stream.
The t-PA antigen concentration and t-PA activity from
the recovered cells remained constant over the 7 months
and were significantly higher (P  .001) from recovered
SMCs from the SMC/tPA grafts than from the control
SMC/lacZ grafts, both before and after G418 selection
(Table I). The t-PA concentration and activity from the
cells isolated from control suprarenal aorta were 0.4  0.0
ng/mL per 105 cells per 24 hours and 0.06 0.02 IU/mL
per 105 cells per 24 hours (n 6). These results are similar
to the data obtained from the control graft, its neointima,
and its underlying aorta.
Intimal thickness. Neointima was observed above
and between the two Dacron grafts (Fig 3, B). The neoin-
tima within the two layers of Dacron grafts was thinner than
that above the grafts. Most of the neointimal layer was
stained blue with Masson trichrome stain (Fig 3, C), indi-
cating that collagen could be a major component. The
thickness of the neointima was not significantly different
between grafts seeded with SMC/tPA and SMC/lacZ (P
.10; Table II). The thickness of the neointima did not
change significantly over the 7 months of the study.
DISCUSSION
The object of this research was to determine the con-
ditions for and the feasibility of sustained therapeutic drug
delivery directly into the circulation. The highest efficiency
of in vivo gene transfer has been previously effected with
adenoviral technology,16,17 but is associated with toxicity
and untoward immunologic responses in vivo. Adeno-
associated viral (AAV) vectors are equally efficient, but are
less toxic.18 Neither requires the target cell to be prolifer-
ating. We did not choose these vectors, because expression
of the transgene is transient. Whether the AAV transgene
integrates into the nuclear DNA or remains episomal is still
under investigation. The episomal transgene would not
pass to both progeny after mitosis. This would cause the
Table II. Neointima thickness (mm) on Dacron stent graf
Duration of
implantation (mo)
SMC/t-PA 	 lacZ
Between struts Ov
2 0.80  0.09 0
3 0.84  0.11 0
4 0.80  0.21 0
5 1.00  0.02 0
7 0.94  0.15 0
SMC, Smooth muscle cells; t-PA, tissue plasminogen activator; NA, not ap
*Dacron grafts were seeded with either SMC/t-PA	 lacZ or SMC/lacZ, an
and paraffin-embedded. Neointima thickness was measured between the ste
The mean  SD was tabulated in millimeters.loss of the desired transgene during graft neointima forma-
tion after the cell attrition from the trauma of stent-graft
implantation. In addition, AAV vectors carry single-
stranded DNA. As long as 6 weeks may be needed for
efficient double-stranded DNA synthesis and gene expres-
sion,19 in contrast to a retrovirally transduced gene, which
begins to function within a few days.
We selected a retroviral vector to confer long-term
gene expression that would be passed on to the SMC
progeny. The retroviral SMC engineering was performed
ex vivo to avoid toxicity. Moreover, we targeted hardy
vascular SMCs, which divide readily in culture, fulfilling a
requirement for retroviral gene transfer.
By using the MuLV vector pseudotyped with VSV-G
we were able to effect highly efficient retroviral gene trans-
fer; a single gene construct could be transferred to more
than 90% of the cell population.20 The selection and reex-
pansion steps previously needed were no longer necessary
to purify the cell population. Avoidance of this prolonged
period diminished the risk of in vitro phenotypic cell
change. For example, vascular SMCs tended to become
more like fibroblasts after 2 weeks of in vitro culture.
Historically, the retention of seeded cells on PTFE and
Dacron vascular grafts has been poor, in part owing to the
manner of surgical implantation. During the traditional
suturing of an anastomosis, cell hypothermia and dehydra-
tion occur. Moreover, after implantation the shear stress
from rapidly flowing blood causes further attrition of the
seeded cell population. To resolve these issues, we used
endograft technology, in which the graft is implanted with
catheter techniques. To overcome the implantation trauma
associated with passing the graft through a sheath, followed
by graft expansion within the artery, we developed the
process of cell suffusion, rather than using simple surface
seeding. The cells are grown in culture throughout the
fibers of the graft wall. Polyurethane carbonate is an effec-
tive supporting matrix for cell suffusion. We reported ex-
cellent cell retention at 1 month in a pig model.15 How-
ever, polyurethane is not clinically used as graft material. In
this study we used a novel bilayered graft, with each layer
fully suffused with cells. Although cells on the luminal side
of the inner layer and on the arterial side of the outer layer
may be injured, cells within the Dacron material and on the
SMC/lacZ
g struts Between struts Overlying struts
0.01 1.0  0.19 0.75  0.13
0.17 1.1  0.35 0.86  0.16
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repopulate the outer layers. The Dacron endograft is lon-
gitudinally crimped so that it readily folds into the deploy-
ment sheath.
This experiment evaluated whether the modifications
described provide a platform for retrovirally engineered
SMCs to be delivered into the circulation, thereby offering
a vehicle for studying this method as a model for direct
intravascular gene therapy. We also assessed gene expres-
sion over a prolonged period (7 months), because sustained
transgene expression is the other important issue. This
experiment was done in dogs rather than in pigs, and SMCs
were used instead of ECs.
The engineered proteins selected for this project in-
cluded the human thrombolytic enzyme t-PA and the
reporter LacZ gene. All cells were co-transduced with the
neomycin analog (G418) resistance gene. This was neces-
sary so that we could select our engineered SMCs at the end
of the experiment from cell ingrowth from the neighboring
artery and from cells deposited from the bloodstream.
The results demonstrate that a retrovirally transduced
gene is detectable for an extended period (7 months) after
SMC implantation in the dog aorta by means of stent-graft
technology. Moreover, t-PA antigen concentration and
expression was constant over the 7 months. We previously
reported successful in vivo delivery of gene products for 1
month with a polyurethane stent graft in a pig model.15 We
have also investigated using PTFE as a suitable con-
duit.14,21 While we were pleased with the performance of
polyurethane stent grafts, this material is not approved
clinically, so we switched to Dacron. SMCs grow well on
Dacron (Fig 2, A). In the present study a bilayered thin
Dacron graft was used, in which both layers were suffused
with cells. While the profile of the dual-layered graft is
thicker than that of a polyurethane stent graft, the graft
could be deployed with catheter technology. We have
experimented with other bilayer grafts, including PTFE
grafts. The inner (luminal layer) pore size is semipermeable;
nutrients, gene product, and metabolic end products are
freely permeable, but cellular elements are not. The reser-
voir behind the semipermeable membrane contains the
engineered SMCs, which are sheltered from sheer stress of
the flowing blood and from the trauma of deployment.
Behind the reservoir is a standard PTFE graft. While the
SMCs do quite well in this environment, Dacron was easier
to work with, though not necessarily better.
Control endografts (no t-PA transduction) were placed
in three of the six dogs. The decision to implant the control
grafts arose after the first three implants. The t-PA data
from the dog killed at 1 month were sufficiently strong that
we needed to exclude artifacts. We postponed killing the
two other dogs in which grafts had already been implanted
until 5 and 7 months. In the next three dogs (killed at 2, 3,
and 4 months) the control endografts were implanted. The
results confirm that there were no artifacts. Since there is
only one dog at each time point, these data are to be
considered pilot data, despite the small standard deviation
between time points.We originally hypothesized that the local secretion of
t-PA could diminish the neointimal thickness. This hypoth-
esis was attributed to the fact that t-PA activates plasmin,
which degrades fibrin, destabilizing thrombus formation.
Plasmin destabilization of the fibrin crosslinking would
diminish platelet adherence. The mitogenic stimulus of
secreting platelets would thus diminish.
On the other hand, t-PA–activated plasmin, a nonspe-
cific serine protease, may in fact digest the extracellular
matrix around the proliferating SMCs. Overexpression of
t-PA decreases EC retention on prosthetic grafts,12-14 pre-
sumably as a result of EC matrix proteolysis. We have
demonstrated that a SMC cellular layer between seeded
ECs and the graft surface enhance EC retention on pros-
thetic grafts.14,21
However, the dog model proved insensitive to these
issues, because the neointimal thickness remained the same
throughout the experiment, even on the control (non–t-
PA) grafts. Moreover, no platelet coagulum was seen on the
control grafts or the test grafts; all were widely patent. Last,
the engineered SMCs expressed human t-PA in this dog
experiment. While no immunogenic reaction was noted, no
inference on the effect of t-PA from the data can be made.
This was beyond the scope of this experiment.
Our next step is to implant endografts containing
SMCs engineered to produce readily detectible gene cod-
ing for a protein deficiency. Specifically, we will be targeting
the factor IX gene, and the implant will be placed in dogs
with hemophilia. We will follow the partial thromboplastin
time monthly. In this way we will not need to explant the
endografts to assay for protein concentration and activity at
monthly intervals. In vivo feasibility data will thus be more
readily obtainable, and we will be able to ascertain whether
an “endograft” can evolve into an “endocrine” graft.
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Available online May 11, 2004.DISCUSSIONDr Timothy Baxter (Omaha, Neb). I think it is a great idea to
use the endograft as a tool to try and deliver drugs. I wonder if you
have thought about using this for the treatment of lower extremity
peripheral vascular disease. We know there is a lot of remodeling
that goes on in vessels, and I wonder if it might be possible to use
this to try and see if you could reverse atherosclerosis or improve
stenosis for lower extremity lesions.
Dr Darwin Eton. We selected tPA because our original
hypothesis was that tPA would change the kinetics of the fibrin
cross linking and destabilize thrombus as it forms on the surface. As
platelets aggregate, they secrete mitogens that can stimulate
smooth muscle cell hyperplasia. We thought tPA would change the
kinetics of this process. This was not observed in this dog model.We saw the reverse in a rabbit model, where intimal hyperplasia was
stimulated; perhaps metalloproteinases are incited or plasmin di-
gests extracellular matrix, exposing smooth muscle cells to mito-
gens.
Dr Baxter. Maybe just one more related question. Have you
considered—and I don’t know if this is even a possibility—but if
you had your cells on the outside of your graft, could you put
something in those cells that would result in aneurysm sac shrink-
age or help to prevent endoleaks?
Dr Eton. SMCs proliferate well. One idea applies SMCs to
treat endoleaks by injecting foam covered with fibroblasts into the
endosac. Proliferation could result in a firm intimal hyperplastic
lesion filling the endosac.
